Autolus Therapeutics vs ImmunityBio
AUTL and IBRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AUTL and IBRX compare
ImmunityBio is the larger company, worth 22 times as much as Autolus Therapeutics ($8.8B against $405M).
Autolus Therapeutics grew revenue faster over the last twelve months (292% versus 193% for ImmunityBio).
Autolus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −239% compared with −599% at ImmunityBio.
ImmunityBio scores higher on the StockData Score (8 against 4 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AUTL | IBRX |
|---|---|---|
| Size and price | ||
| Market cap | $405M | $8.8B |
| Share price | $1.52 | $8.29 |
| Change, 1 year | 4.1% | 243% |
| Change, 5 years | −72.7% | −1.3% |
| Beta (5Y) | 1.83 | 1.61 |
| Employees | 754 | 691 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.4× (better) | 53.0× |
| P/B | 5.4× | – |
| FCF yield | −57.5% | −3.3% (better) |
| Fair value | $1.40 | – |
| Margin of safety | −8.7% | – |
| Growth | ||
| Revenue growth (TTM) | 292% (better) | 193% |
| Revenue growth, 5Y average | – | 185% |
| Profitability | ||
| Gross margin | 15.7% | 99.3% (better) |
| Operating margin | −211% | −152% (better) |
| Net margin | −239% (better) | −599% |
| FCF margin | −198% | −174% (better) |
| Return on equity | −133% | – |
| Financial health | ||
| Interest coverage | −5.9× | – |
| Current ratio | 4.89 | 5.72 (better) |
| Altman Z-score | −4.44 (better) | −7.44 |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 49.7% | 19.1% |
| Held by insiders | 16.9% | 75.3% |
| Insider net buying, 12 months | −$15.7K (better) | −$8.4M |
| Short interest, % of float | – | 47.3% |
Go deeper
- AUTL stock overview
- AUTL income statement
- AUTL valuation and score
- IBRX stock overview
- IBRX income statement
- IBRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.